ArticleOPEN ACCESS

A Pim kinase inhibitor, please

Blood
DOI: 10.1182/blood-2005-03-1150
6Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Hammerman and colleagues have shown that the Pim-2 kinase is required to confer rapamycin resistance in hematopoietic cells, thus providing a strong rationale for the development of Pim kinase inhibitors as potential therapeutic agents in hematologic malignancies.

Cite

CITATION STYLE

APA

Giles, F. (2005, June 1). A Pim kinase inhibitor, please. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2005-03-1150

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free